Alternative treatments of adenomyosis - an update in procedural management and clinical outcomes.

IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY
Alison M Zeccola, Sarah E Allen
{"title":"Alternative treatments of adenomyosis - an update in procedural management and clinical outcomes.","authors":"Alison M Zeccola, Sarah E Allen","doi":"10.1097/GCO.0000000000000972","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Adenomyosis is a common cause of abnormal uterine bleeding (AUB), dysmenorrhea, and pelvic pain. Definitive diagnosis and treatment have historically been by uterine histopathology at time of hysterectomy; however, advances in imaging have supported earlier diagnosis and subsequent conservative treatment. This review aims to update the evidence supporting the uterine-sparing, procedural management options with a focus on clinical outcomes.</p><p><strong>Recent findings: </strong>Uterine artery embolization (UAE), radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), percutaneous microwave ablation (PMWA), and adenomyomectomy are minimally invasive interventions proven to be effective in reducing AUB and dysmenorrhea due to adenomyosis. Symptom improvement is associated with a decrease in uterine volume. Studies support the use of alternative treatment options given the overall low rates of symptom recurrence and reintervention. Combination therapy may be more effective than monotherapy.</p><p><strong>Summary: </strong>This review provides the current evidence for use of alternative treatment options for adenomyosis. Access to ablative therapies in the USA is limited and primarily off label, given lack of FDA approval. High-quality prospective and randomized controlled trials are needed in order to further delineate treatment comparisons, efficacy, safety, and ideal patient selection for these treatments. More data are needed to assess safety and utility in those desiring future fertility.</p>","PeriodicalId":55194,"journal":{"name":"Current Opinion in Obstetrics & Gynecology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GCO.0000000000000972","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Adenomyosis is a common cause of abnormal uterine bleeding (AUB), dysmenorrhea, and pelvic pain. Definitive diagnosis and treatment have historically been by uterine histopathology at time of hysterectomy; however, advances in imaging have supported earlier diagnosis and subsequent conservative treatment. This review aims to update the evidence supporting the uterine-sparing, procedural management options with a focus on clinical outcomes.

Recent findings: Uterine artery embolization (UAE), radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), percutaneous microwave ablation (PMWA), and adenomyomectomy are minimally invasive interventions proven to be effective in reducing AUB and dysmenorrhea due to adenomyosis. Symptom improvement is associated with a decrease in uterine volume. Studies support the use of alternative treatment options given the overall low rates of symptom recurrence and reintervention. Combination therapy may be more effective than monotherapy.

Summary: This review provides the current evidence for use of alternative treatment options for adenomyosis. Access to ablative therapies in the USA is limited and primarily off label, given lack of FDA approval. High-quality prospective and randomized controlled trials are needed in order to further delineate treatment comparisons, efficacy, safety, and ideal patient selection for these treatments. More data are needed to assess safety and utility in those desiring future fertility.

子宫腺肌症的替代治疗--程序管理和临床结果的最新进展。
审查目的:子宫腺肌症是导致异常子宫出血(AUB)、痛经和盆腔疼痛的常见原因。明确的诊断和治疗历来都是在子宫切除术时通过子宫组织病理学进行的;然而,影像学的进步支持了更早的诊断和随后的保守治疗。本综述旨在更新支持保宫手术治疗方案的证据,重点关注临床结果:最新研究结果:子宫动脉栓塞术(UAE)、射频消融术(RFA)、高强度聚焦超声(HIFU)、经皮微波消融术(PMWA)和子宫腺肌症切除术都是微创介入疗法,已被证实能有效减少子宫腺肌症和子宫腺肌症引起的痛经。症状的改善与子宫体积的缩小有关。鉴于症状复发和再次干预的总体比率较低,研究支持使用替代治疗方案。综合疗法可能比单一疗法更有效。摘要:本综述提供了目前使用替代疗法治疗子宫腺肌症的证据。在美国,由于缺乏美国食品及药物管理局(FDA)的批准,使用消融疗法的机会有限,而且主要是非标签疗法。需要进行高质量的前瞻性随机对照试验,以进一步确定这些疗法的治疗比较、疗效、安全性和理想的患者选择。还需要更多的数据来评估这些疗法对希望将来生育的患者的安全性和实用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
104
审稿时长
6-12 weeks
期刊介绍: ​​​​​​​Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With eleven disciplines published across the year – including reproductive endocrinology, gynecologic cancer and fertility– every issue also contains annotated references detailing the merits of the most important papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信